The British Journal of Clinical Pharmacology

Volume 53
2002

Published for
The British Pharmacological Society by
Blackwell Science

© 2002 Blackwell Science Ltd (A Blackwell Publishing Company)
Osney Mead, Oxford OX2 0EL
25 John Street, London WC1N 2BL
23 Ainslie Place, Edinburgh EH3 6AJ
Commerce Place, 350 Main Street, Malden MA 02148-5018, USA
54 University Street, Carlton, Victoria 3053, Australia

Other Editorial Offices:
Blackwell Wissenschafts-Verlag GmbH
Kurfürstendamm 57
1707 Berlin
Germany

Blackwell Science KK
MG Kodenmacho Building
7–10 Kodenmacho Nihombashi
Chuo-ku, Tokyo 104
Japan

Published on behalf of
The British Pharmacological Society

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without the prior permission of the copyright owner. Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Blackwell Science for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of $15.00 per copy is paid directly to CCC, 222 Rosewood Drive, Suite 910, Danvers, MA 01923, USA. 0206-5251/01 $15.00/0. (For copying beyond that permitted by Sections 107 or 108 of the US Copyright Law). This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale. Special requests should be addressed to the Editor.

Typeset, Printed and Bound by The Charlesworth Group, Huddersfield

Contents

This article is considered particularly suitable for continuing medical education.

Volume 53, Number 1, January 2002

Editorial

1 The Journal moves online for submission and peer review: *M.S. Lennard, J.M. Ritter, E.J. Begg & G.T. Tucker*

Review series

Review Series on Pharmacogenomics edited by Prof. M. Pirmohamed

3 Pharmacogenetics of asthma: *A. Fenech & I.P. Hall*

Pharmacokinetics

17 Distribution of venlafaxine and its O-desmethyl metabolite in human milk and their effects in breastfed infants: *K.F. Ilett, J.H. Kristensen, L.P. Hackett, M. Paech, R. Kohan & J. Rampono*

23 The pharmacokinetic properties of intramuscular artesunate and rectal dihydroartemisinin in uncomplicated falciparum malaria: *K.F. Ilett, K.T. Batty, S.M. Powell, T.Q. Binh, L.T.A. Thu, H.L. Phuong, N.C. Hung & T.M.E. Davis*

Pharmacodynamics

31 The impact of antihypertensive drug groups on urinary albumin excretion in a non-diabetic population: *T.B.M. Monster, W.M.T. Janssen, P.E. de Jong & L.T.W de Jong-van den Berg*

37 Effect of aspirin on vasodilation to bradykinin and substance P in patients with heart failure treated with ACE inhibitor: *A.P. Davie & J.J.V. McMurray*

43 A new laser pain threshold model detects a faster onset of action from a liquid formulation of 1 g paracetamol than an equivalent tablet formulation: *J.A. Sutton, W.P. Gillin, T.J. Grattan, G.D. Clarke & S.G. Kilminster*

Pharmacokinetics/pharmacodynamics

49 Pharmacokinetics and anticonvulsant effects of diazepam in children with severe falciparum malaria and convulsions: *B.R. Ogutu, C.R.J.C. Newton, J. Crawley, S.N. Muchohi, G.O. Otieno, G. Edwards, K. Marsh & G.O. Kokwaro*

59 Pharmacodynamic effect of continuous *vs* intermittent dosing of dofetilide on QT interval: *M.J. Allen, S.D. Oliver, M.W. Newgreen & D.J. Nichols*

Drug disposition

67 The effects of an oral contraceptive containing ethinyloestradiol and norgestrel on CYP3A activity: *D.J. Belle, J.T. Callaghan, J.C. Gorski, J.F. Maya, O. Mousa, S.A. Wrighton & S.D. Hall*

75 St John's Wort increases expression of P-glycoprotein: Implications for drug interactions.: *M. Hennessy, D. Kelleher, J.P. Spiers, M. Barry, P. Kavanagh, D. Back, F. Mulcahy & J. Feely*

Drug interaction

83 Randomized cross-over clinical trial to study potential pharmacokinetic interactions between cisplatin or carboplatin and etoposide: *H.D. Thomas, D.J. Porter, I. Bartelink, J.R. Nobbs, M. Cole, S. Elliott, D.R. Newell, A.H. Calvert, M. Highley & A.V. Boddy*

Therapeutics

93 What benefit do patients expect from adding second and third antihypertensive drugs?: *H. Leaman & P.R. Jackson*

Pharmacovigilance

101 Statins and the risk of idiopathic venous thromboembolism: *C.-C. Yang, S.S. Jick & H. Jick*

Short report

107 Comparison of the clinical efficacy of standard and mucoadhesive-based nasal decongestants: *C.T. Tzachev, M. Mandajieva, E.H. Minkov & T.A. Popov*

Volume 53, Number 2, February 2002

Review series

Review Series on Pharmacogenetics edited by Prof. M. Pirmohamed

111 Molecular genetics of CYP2D6: Clinical relevance with focus on psychotropic drugs: *L. Bertilsson, M.-L. Dahl, P. Dalén & A. Al-Shurbaji*

Review

123 The promise of new antiepileptic drugs: *J.S. Duncan*

Pharmacokinetics

133 Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy

volunteers: *E.L. Swart, B. van der Hoven, A.B.J. Groeneveld, D.J. Touw & M. Danhof*

141 Pharmacokinetics of a contraceptive patch (Evra™/Ortho Evra™) containing norelgestromin and ethinyloestradiol at four application sites: *L.S. Abrams, D.M. Skee, J. Natarajan, F.A. Wong & G.D. Anderson*

Pharmacokinetics/pharmacodynamics

147 Dose-effect relationship for several coagulation markers during administration of the direct thrombin inhibitor S 18326 in healthy subjects: *P. Gaussem, M. Dubar, B. le Bonniec, I. Richard-Lordereau, R. Jochemsen & M. Aiach*

Drug disposition

155 Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects: *R.F. Frye & R.A. Branch*

Therapeutics

163 Management of *Helicobacter pylori* eradication – the influence of structured counselling and follow-up: *F.A. Al-Eidan, J.C. McElnay, M.G. Scott & J.B. McConnell*

Pharmacovigilance

173 Upper gastrointestinal bleeding among users of NSAIDs: a population-based cohort study in Denmark: *L. Mellemkjær, W.J. Blot, H.T. Sørensen, L. Thomassen, J.K. McLaughlin, G.L. Nielsen & J.H. Olsen*

183 Contraindicated NSAIDs are frequently prescribed to elderly patients with peptic ulcer disease: *L.E. Visser, H.H. Graatsma & B.H.Ch. Stricker*

Short reports

189 Inhibition of basal nitric oxide synthesis increases aortic augmentation index and pulse wave velocity *in vivo*: *I.B. Wilkinson, H. MacCallum, J.R. Cockcroft & D.J. Webb*

193 Local nitric oxide release does not affect tachyphylaxis to angiotensin II in dorsal hand veins in man in the presence of prostaglandin synthesis inhibition: *S.L. de Haas, I.B. Wilkinson, J.L. Boyd & D.J. Webb*

196 Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon: *B.M. Stone, C. Turner, S.L. Mills, I. Paty, A. Patat, M. Darwish & P. Danjou*

203 The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects: *S. Saima, K. Furnie, H. Yoshimoto, J. Fukuda, T. Hayashi & H. Echizen*

207 Frequency of adverse drug reactions in children: A prospective study: *A.P. Jonville-Béra, B. Giraudeau, P. Blanc, F. Beau-Salinas & E. Autret-Leca*

Letters to the Editors

211 Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study: *R.P.G. van Heeswijk, J.W.T. Cohen Stuart, D.M. Burger, J.H. Beijnen, J.C.C. Borleffs & R.M.W. Hoetelmans*

212 Pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase efavirenz: *R. Calvo, J.C. Lukas, M. Rodriguez, M.A. Carlos & E. Suarez*

214 Recreational bupropion abuse in a teenager: *J. McCormick*

Book reviews

215 Review for Graduate Therapeutics: A Primer for MRCP and Specialist Training: *N.S. Baber*

215 Muscarinic receptors in airways diseases: *A.H. Morice*

216 Modern immunosuppressives: *A.T. Raftery*

218 Corrigendum

Volume 53, Number 3, March 2002

Editorial

219 Clinical update on sildenafil citrate: *I.H. Osterloh & A. Riley*

Review series

Review Series on Pharmacogenetics edited by Prof. M. Pirmohamed

224 Maximizing the value of medicines by including pharmacogenetic research in drug development and surveillance: *C. Brazell, A. Freeman & M. Mosteller*

Pharmacokinetics

232 Pharmacokinetics of moxifloxacin, a novel 8-methoxy-quinolone, in patients with renal dysfunction: *H. Stass, D. Kubitza, A. Halabi & H. Delesen*

238 Sex and age differences in the pharmacokinetics of alosetron: *K.M. Koch, J.L. Palmer, N. Noordin, J.J. Tomlinson & C. Baidoo*

Pharmacodynamics

243 Efficacy of calcium channel blockers as maintenance therapy for asthma: *M.A. Twiss, E. Harman, S. Chesrown & L. Hendeles*

250 Comparative activity of cetirizine and mizolastine on histamine-induced skin wheal and flare responses at 24 h: *A. Purohit, M. Mélac, G. Pauli & N. Frossard*

255 Limitation of the *in vitro* whole blood assay for predicting the COX selectivity of NSAIDs in clinical use: *H. Blain, C. Boileau, F. Lapicque, E. Nédélec, D. Lœuille, C. Guillaume, A. Gaucher, C. Jeandel, P. Netter & J.-Y. Jouzeau*

266 5-HT_{1B}-receptors and vascular reactivity in human isolated blood vessels: assessment of the potential craniovascular selectivity of sumatriptan: *Z. Razzaque, J.D. Pickard, Q.-P. Ma, D. Shaw, K. Morrison, T. Wang & J. Longmore*

275 Investigation of the effect of chlormethiazole on cerebral chemistry in neurosurgical patients: a combined study of microdialysis and a neuroprotective agent: *P.J. Hutchinson, M.T. O'Connell, J.P. Coles, D.A. Chatfield, M.R. Coleman, P.G. Al-Rawi, C.R. Kett-White, A.K. Gupta, D.K. Menon, S.J. Boniface, M. Heazell, P.J. Kirkpatrick & J.D. Pickard*

Pharmacokinetics/pharmacodynamics

284 Levormeloxifene: safety, pharmacodynamics and pharmacokinetics in healthy postmenopausal women following single and multiple doses of a new selective oestrogen receptor modulator: *B.K. Skrumsager, B. Kiehr, P.C. Pedersen, M. Gerrits, N. Watson & K. Bjarnason*

296 Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: Correlation between cognitive impairment and plasma drug concentration: *M. Tagawa, M. Kano, N. Okamura, M. Higuchi, M. Matsuda, Y. Mizuki, H. Arai, T. Fujii, S. Komemushi, M. Itoh, H. Sasaki, T. Watanabe & K. Yanai*

305 Early clinical experience with the novel NMDA receptor antagonist CNS 5161 : *M.R. Walters, A.P.J. Bradford, J. Fischer & K.R. Lees*

Clinical toxicology

312 Activated charcoal alone or after gastric lavage: a simulated large paracetamol intoxication: *A.B. Christophersen, D. Levin, L.C.G. Hoegberg, H.R. Angelo & J.P. Kampmann*

Pharmacovigilance

318 Patient reporting of potential adverse drug reactions: a methodological study: *N. Jaremsiripornkul, J. Krska, P.A.G. Capps, R.M.E. Richards & A. Lee*

Short reports

326 Hospital prescribing errors: epidemiological assessment of predictors: *R. Fijn, P.M.L.A. Van den Bemt, M. Chow, C.J. De Blaey, L.T.W. De Jong-Van den Berg & J.R.B.J. Brouwers*

332 Flow-mediated nitric oxide activity in the forearm vasculature of premenopausal women: *D.O.C. Anumba, S.C. Robson & G.A. Ford*

Letters to the Editors

337 The influence of body weight on the pharmacokinetics of mefloquine: *J.A. Simpson, L. Aarons, R. Price & N.J. White*

338 Paracetamol can exacerbate irradiation-induced DNA damage: *A. Curnow, L. Salter, N. Morley, S. Campbell & D. Gould*

Volume 53, Number 4, April 2002

Review

341 What knowledge and skills are essential for specialists in Clinical Pharmacology and Therapeutics? Results of a Delphi study: *J.C. Mucklow*

Pharmacokinetics

347 The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide: *R.T. Penson, S.P. Joel, M. Roberts, A. Gloyne, S. Beckwith & M.L. Slevin*

Pharmacokinetics/pharmacodynamics

355 Pharmacokinetics and pharmacodynamics of tezosentan, an intravenous dual endothelin receptor antagonist, following chronic infusion in healthy subjects: *J. Dingemanse, M. Clozel & P.L.M. van Giersbergen*

Pharmacovigilance

363 Association between antidepressant drug use and hyponatraemia: a case-control study: *K.L.L. Movig, H.G.M. Leufkens, A.W. Lenderink, V.G.A. van den Akker, P.P.G. Hodiamont, H.M.J. Goldschmidt & A.C.G. Egberts*

370 Non-sedating antihistamine drugs and cardiac arrhythmias – biased risk estimates from spontaneous reporting systems?: *M.L. De Bruin, E.P. van Puijenbroek, A.C.G. Egberts, A.W. Hoes & H.G.M. Leufkens*

Pharmacoepidemiology

375 High persistence of statin use in a Danish population: Compliance study 1993–1998: *J. Larsen, M. Andersen, J. Kragstrup & L.F. Gram*

379 Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminated?: *A.K. Mantel-Teeuwisse, O.H. Klungel, W.M.M. Verschuren, A.J. Porsius & A. de Boer*

Short reports

386 Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation: *S. Cremers, R. Schoemaker, R. Bredius, J. den Hartigh, L. Ball, I. Twiss, P. Vermeij & J. Vossen*

390 Pharmacokinetics and metabolism of oral midazolam in preterm infants: *S.N. de Wildt, G.L. Kearns, W.C.J. Hop, D.J. Murry, S.M. Abdel-Rahman & J.N. van den Anker*
393 Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19: *J.-Y. Cho, K.-S. Yu, I.-J. Jang, B.-H. Yang, S.-G. Shin & D.-S. Yim*
398 Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine: *S. O'Riordan, E. Ouldred, S. Brice, S.H.D. Jackson & C.G. Swift*

Letters to the Editors
403 A possible interaction between lithium and rofecoxib: *J. Lundmark, T. Gunnarsson & F. Bengtsson*
404 Syncope following oral chloroquine administration in a hypertensive patient controlled on amlodipine: *A.A.L. Ajayi & A.Q. Adigun*
405 Amlodipine and grapefruit juice: *M. Josefsson & J. Ahlner*
406 A reply: *J. Vincent, S. Harris, G. Foulds, L. Dogolo, S. Willavize & H. Friedman*
407 β-adrenoceptor blockers and serotonin: *T. Terao*
407 Confidence intervals, misclassification of exposure and risk of suicide in users of β-adrenoceptor blockers: a reply: *H.T. Sørensen, L. Mellemkjær & J.H. Olsen*
408 CYP2C9 polymorphism and warfarin dose requirements: *A.K. Daly, C.P. Day & G.P. Aithal*
409 CYP2C9 polymorphisms and CYP2C9*2 genotyping primers: *J.A. Goldstein*

Book review
411 Recombinant protein drugs: *P. Lewis*

Proceedings of the BPS
413 Proceedings of the British Pharmacological Society, London, 18–20 December 2001

449 Corrigendum

Volume 53, Number 5, May 2002

Case report
451 Lead poisoning: case studies: *J.N. Gordon, A. Taylor & P.N. Bennett*

Population pharmacokinetics
459 Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials: *L. Nguyen, B. Tranchand, C. Puozzo & P. Variol*

Pharmacodynamics
469 Metformin does not enhance ovulation induction in clomiphene resistant polycystic ovary syndrome in clinical practice: *N.D.C. Sturrock, B. Lannon & T.N. Fay*

Pharmacokinetics/pharmacodynamics
474 Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation: *M.H. Magee, R.A. Blum, C.D. Lates & W.J. Jusko*
485 Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin: *J. Dingemanse, C. Meyerhoff & J. Schadrack*
492 Dose-finding and efficacy study for i.m. artemotil (beta-arteether) and comparison with i.m. artemether in acute uncomplicated *P. falciparum* malaria: *S. Looareesuwan, B. Oosterhuis, B.M. Schilizzi, F.A.E. Sollie, P. Wilairatana, S. Krudsood, Ch.B. Lugt, P.A.M. Peeters & J.O. Peggins*
501 Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers: *P.D. Knoester, D.M. Jonker, R.T.M. van der Hoeven, T.A.C. Vermeij, P.M. Edelbroek, G.J. Brekelmans & G.J. de Haan*
508 Pharmacokinetics and pharmacodynamics of combination chemotherapy with paclitaxel and epirubicin in breast cancer patients: *R. Danesi, F. Innocenti, S. Fogli, A. Gennari, E. Baldini, A. Di Paolo, B. Salvadori, G. Bocci, P.F. Conte & M. Del Tacca*

Drug disposition
519 The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine: *S.U. Yasuda, P. Zannikos, A.E. Young, K.M. Fried, I.W. Wainer & R.L. Woosley*
526 *MDR1* gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine: *S. Drescher, E. Schaeffeler, M. Hitzl, U. Hofmann, M. Schwab, U. Brinkmann, M. Eichelbaum & M.F. Fromm*

Toxicology
535 Concomitant overdosing of other drugs in patients with paracetamol poisoning: *L.E. Schmidt & K. Dalhoff*

Book review
542 Antiviral agents: advances and problems: *W. Rawlinson*

Proceedings
543 Proceedings of the Dutch Society for Clinical Pharmacology and Biopharmacy, 8 October 2001

Volume 53, Number 6, June 2002

Review series

Research Methods in Human Cardiovascular Pharmacology edited by Dr S. Maxwell and Prof. D. Webb

561 Invasive assessment of the coronary circulation: intravascular ultrasound and Doppler: *D.E. Newby & K.A.A. Fox*

Pharmacokinetics

576 Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid cremophor EL: *M. Martin-Facklam, J. Burhenne, R. Ding, R. Fricker, G. Mikus, I. Walter-Sack & W.E. Haefeli*

582 The effect of food on the pharmacokinetics of nifedipine in two slow release formulations: pronounced lag-time after a high fat breakfast: *B.S. Schug, E. Brendel, E. Chantraine, D. Wolf, W. Martin, R. Schall & H.H. Blume*

Drug interaction

589 Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole: *P.L.M. van Giersbergen, A. Halabi & J. Dingemanse*

Drug disposition

596 Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (*DPYD*) in the Egyptian population: *S.I. Hamdy, M. Hiratsuka, K. Narahara, M. El-Enany, N. Moursi, M.S.-E. Ahmed & M. Mizugaki*

Pharmacodynamics

604 Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind-up of the second pain response in healthy male volunteers: *A.M. Hughes, J. Rhodes, G. Fisher, M. Sellers & J.W. Growcott*

613 Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage *ayahuasca* in healthy volunteers: *J. Riba, P. Anderer, A. Morte, G. Urbano, F. Jané, B. Saletu & M.J. Barbanoj*

Therapeutics

629 Analgesic efficacy of sustained release paracetamol in patients with osteoarthritis of the knee: *T.H. Bacon, J.G. Hole, M. North & I. Burnett*

Pharmacovigilance

637 Clinical risk factors for venous thromboembolus in users of the combined oral contraceptive pill: *C. Black, J.A. Kaye & H. Jick*

Short reports

641 Effects of oral monosodium (L)-glutamate on insulin secretion and glucose tolerance in healthy volunteers: *H. Chevassus, E. Renard, G. Bertrand, I. Mourand, R. Puech, N. Molinier, J. Bockaert, P. Petit & J. Bringer*

644 A comparison of the effects of nabumetone *vs* meloxicam on serum thromboxane B_2 and platelet function in healthy volunteers: *D.J.W. van Kraaij, A.H.I. Hovestad-Witterland, M. de Metz & E.J. Vollaard*

Book review

648 Neurotransmitters, drugs and brain function: *J.S. Duncan*

649 Announcements

651 Indices for Volume 53

Volume 53, Supplement 1, 2002

1S Introduction: *G. Edwards & G. J. Muirhead*

5S Pharmacokinetics of sildenafil citrate after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality: *D. J. Nichols, G. J. Muirhead & J. A. Harness*

13S Comparative human pharmacokinetics and metabolism of single-dose oral and intravenous sildenafil citrate: *G. J. Muirhead, D. J. Rance, D. K. Walker & P. Wastall*

21S The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate: *G. J. Muirhead, K. Wilner, W. Colburn, G. Haug-Pihale & B. Rouviex*

31S The effects of cimetidine and antacid on the pharmacokinetic profile of sildenafil citrate in healthy male volunteers: *K. Wilner, L. Laboy & M. LeBel*

37S The effects of steady-state erythromycin and azithromycin on the pharmacokinetics of sildenafil citrate in healthy volunteers: *G. J. Muirhead, S. Faulkner, J. A. Harness & J. Taubel*

45S A population pharmacokinetic analysis of sildenafil citrate in patients with erectile dysfunction: *P. A. Milligan, S. F. Marshall & M. O. Karlsson*

53S The effects of sildenafil citrate on human sperm function in healthy volunteers: *K. Purvis, G. J. Muirhead & J. A. Harness*

61S Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction: *I. Eardley, P. Ellis, M. Boolell & M. Wulff*